Abstract
BackgroundTwo independent controlled randomized trials demonstrated the efficacy and safety of rituximab (RTX) monotherapy in severe cryoglobulinemic vasculitis (CV) (1, 2), with one reporting a prolonged follow-up (1).ObjectivesTo report the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have